27.49
-1.18 (-4.12%)
| Previous Close | 28.67 |
| Open | 29.24 |
| Volume | 391,897 |
| Avg. Volume (3M) | 972,755 |
| Market Cap | 2,887,989,504 |
| Price / Book | 5.76 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 |
| Diluted EPS (TTM) | -2.03 |
| Total Debt/Equity (MRQ) | 3.41% |
| Current Ratio (MRQ) | 5.34 |
| Operating Cash Flow (TTM) | -100.04 M |
| Levered Free Cash Flow (TTM) | -48.76 M |
| Return on Assets (TTM) | -27.09% |
| Return on Equity (TTM) | -108.40% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Metsera, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | 2.13 |
|
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 13.06% |
| % Held by Institutions | 37.85% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alpha Wave Global, Lp | 31 Mar 2025 | 2,384,050 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Wells Fargo, 136.45%) | Buy |
| Median | 63.50 (130.99%) | |
| Low | 62.00 (Guggenheim, 125.54%) | Buy |
| Average | 63.50 (130.99%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 31.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 20 Jun 2025 | 65.00 (136.45%) | Buy | 27.71 |
| Guggenheim | 10 Jun 2025 | 62.00 (125.54%) | Buy | 35.10 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Jun 2025 | Announcement | Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference |
| 09 Jun 2025 | Announcement | Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i |
| 05 Jun 2025 | Announcement | Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association® |
| 12 May 2025 | Announcement | Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress |
| 08 May 2025 | Announcement | Metsera to Present at Bank of America 2025 Global Healthcare Conference |
| 26 Mar 2025 | Announcement | Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |